Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib vs Pemetrexed Maintenance in EGFR+ NSCLC (MARBLE)
NCT02488694Phase 2Terminated
- Sponsor
- AIO-Studien
- Start
- Nov 2015
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of afatinib in non-small cell lung cancer (NSCLC), sponsored by AIO-Studien. Started Nov 2015; status: terminated.
02
Drugs
afatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02488694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02488694.